TCTR20220908007尚未招募1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Dapagliflozin 10 mg Film-coated Tablet and Reference Product (ForxigaTM 10) in Healthy Thai Volunteers under Fasting Conditions
International Bio Service Co., Ltd0 个研究点目标入组 42 人开始时间: 2022年9月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Healthy Thai male or female subjects between the ages of 18 to 55 years
- •2. Body mass index between 18.0 to 30.0 kg per square meter
- •3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening.
- •Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study.
- •4. Non-pregnant woman (negative pregnancy test) and not currently breast feeding.
- •5. Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1:
- •- Postmenopausal for at least 1 year or
- •- Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months
- •6. Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2.
- •7. Have voluntarily given written informed consents (signed and dated) by the subject prior to participating in this study.
排除标准
- •1. History of allergic reaction or hypersensitivity to dapagliflozin or to any of the excipients
- •2. History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper/hypothyroidism, diabetes mellitus), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper/hypotension), psychiatric (e.g. depression), neurologic (e.g. convulsion), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness
- •3. Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19
- •4. History about administration of COVID-19 vaccine within 30 days prior to check-in in each Period.
- •5. Have abnormality of glucose (FBS)
- •6. History or evidence of type 1 diabetes mellitus, diabetic ketoacidosis
- •7. History or evidence of heart failure
- •8. History or evidence of volume depletion, hypotension, electrolyte imbalances
- •9. History or evidence of genital mycotic infections, urinary tract infections within 14 days prior to check-in in each period
- •10. History or evidence of necrotizing fasciitis of the perineum (fournier is gangrene)
- •11. History or evidence of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption
- •12. History or evidence of severe hepatic impairment
- •13. Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy
- •14. History of problems with swallowing tablet or capsule
- •15. History of sensitivity to heparin or heparin-induced thrombocytopenia
- •16. History of vomiting or diarrhea within 24 hours prior to check-in in each period
- •17. 12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject is eligibility.
- •18. Investigation with blood sample shows positive test for HBsAg.
研究者
相似试验
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Pregabalin 50 mg Capsules and Reference Product (LyricaTM) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20240427011International Bio Service30
尚未招募
1 期
Bioequivalence Study of Levetiracetam 500 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerLevetiracetam, Bioequivalence Study, Healthy Thai VolunteerTCTR20230905002International Bio Service Co., Ltd.26
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Donepezil Hydrochloride 10 mg Orodispersible Tablets and Reference Product (Aricept Evess 10 mg) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersDonepezil Hydrochloride 10 mg Orodispersible TabletsBioequivalence StudyHealthy Thai VolunteersTCTR20210121002International Bio Service Co., Ltd.34
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Duloxetine 60 mg Hard Gastro-resistant Capsules and Reference Product (Cymbalta) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study in Healthy Thai VolunteersDuloxetine 60 mg Hard Gastro-resistant Capsules and Reference Product (Cymbalta) in Healthy Thai Volunteers under Fasting ConditionsTCTR20240701004International Bio Service Co., Ltd.60
尚未招募
1 期
Bioequivalence Study of Entecavir 0.5 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerEntecavir, Bioequivalence Study, Healthy Thai VolunteerTCTR20210709001International Bio Service Co., Ltd.34